• Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.

  Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud J, Davicioni E, Liu S, Heemers HV.
  Eur Urol Open Sci. 2020 Dec;22:34-44. doi: 10.1016/j.euros.2020.10.002.

• Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T.

  Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L.
  Cancer Immunol Res. 2020 Dec;8(12):1496-1507. doi: 10.1158/2326-6066.CIR-20-0252.

• Immunotherapy Use in Patients with Lung Cancer and Comorbidities.

  von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE.
  Cancer J. Nov/Dec 2020;26(6):525-536. doi: 10.1097/PPO.0000000000000484.

• Engineering cytokines and cytokine circuits.

  Li AW, Lim WA.
  Science. 2020 Nov 27;370(6520):1034-1035. doi: 10.1126/science.abb5607.

• Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.

  Li S, Bennett ZT, Sumer BD, Gao J.
  Acc Chem Res. 2020 Nov 17;53(11):2546-2557. doi: 10.1021/acs.accounts.0c00475.

• Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation.

  Becher LRE, Nevala WK, Sutor SL, Abergel M, Hoffmann MM, Parks CA, Pease LR, Schrum AG, Markovic SN, Gil D.
  Blood Adv. 2020 Nov 10;4(21):5343-5356. doi: 10.1182/bloodadvances.2020002255.

• Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window.

  Wang X, Wilhelm J, Li W, Li S, Wang Z, Huang G, Wang J, Tang H, Khorsandi S, Sun Z, Evers B, Gao J.
  Nat Commun. 2020 Nov 17;11(1):5828. doi: 10.1038/s41467-020-19651-7.

• Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.

  Wang H, Najibi AJ, Sobral MC, Seo BR, Lee JY, Wu D, Li AW, Verbeke CS, Mooney DJ.
  Nat Commun. 2020 Nov 10;11(1):5696. doi: 10.1038/s41467-020-19540-z.

• Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.

  Lundh S, Jung I, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.
  Clin Exp Med. 2020 Nov;20(4):469-480. doi: 10.1007/s10238-020-00628-1.

• Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.

  Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams Si, Liu S, Ito F.
  Nat Commun. 2020 Oct 27;11(1):5415. doi: 10.1038/s41467-020-19192-z.

• Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

  Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M.
  J Am Acad Dermatol. 2020 Oct;83(4):1130-1143. doi: 10.1016/j.jaad.2020.04.105.

• An inflammatory cytokine signature predicts COVID-19 severity and survival.

  Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S.
  Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9.

• HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.

  Ren S, Gaykalova DA, Guo T, Favorov AV, Fertig EJ, Tamayo P, Callejas-Valera JL, Allevato M, Gilardi M, Santos J, Fukishimi T, Sakai A, Ando M, Sadat S, Liu C, Xu G, Fisch KM, Wang Z, Molinolo AA, Gutkind JS, Ideker T, Koch WM, Califano JA.
  Oncogene. 2020 Oct;39(40):6327-6339. doi: 10.1038/s41388-020-01431-8.

• Fructose stimulated de novo lipogenesis is promoted by inflammation.

  Todoris J, Caro GD, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M.
  Nat Metab. 2020 Oct;2(10):1034-1045. doi: 10.1038/s42255-020-0261-2.

• Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease.

  Badachhape AA, Working PK, Srivastava M, Bhandari P, Stupin IV, Devkota L, Tanifum EA, Annapragada AV, Ghaghada KB.
  Sci Rep. 2020 Sep 30;10(1):16185. doi: 10.1038/s41598-020-73233-7.

• MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

  Kufe D.
  Carcinogenesis. 2020 Sep 24;41(9):1173-1183. doi: 10.1093/carcin/bgaa082.

• Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

  Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, Levinson S, Stark SR, Yao V, Tadych A, Troyanskaya OG, Lim WA.
  Cell Syst. 2020 Sep 23;11(3):215-228.e5. doi: 10.1016/j.cels.2020.08.002.

• Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

  Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, Spencer A.
  Br J Haematol. 2020 Sep 18. doi: 10.1111/bjh.17080.

• Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).

  Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, Wilson KM, Onel K, Geanon D, Tuballes K, Patel M, Mouskas K, O'Donnell T, Merritt E, Simons NW, Barcessat V, Del Valle DM, Udondem S, Kang G, Gangadharan S, Ofori-Amanfo G, Laserson U, Rahman A, Kim-Schilze S, Charney AW, Gnjatic S, Gelb BD, Merad M, Bogunovic D.
  Cell. 2020 Sep 14;S0092-8674(20)31231-9. doi: 10.1016/j.cell.2020.09.034.

• Inhibition of LSD1 in MDS progenitors restores differentiation of CD141 ^Hi conventional dendritic cells.

  Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SL, Griffiths EA, Nemeth MJ.
  Leukemia. 2020 Sep;34(9):2460-2472. doi: 10.1038/s41375-020-0765-5.

• Inhibition of LSD1 in MDS Progenitors Restores Differentiation of CD141Hi Conventional Dendritic Cells.

  Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Sait SNJ, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI,Griffiths EA, Nemeth MJ.
  Leukemia. 2020 Sep;34(9):2460-2472. doi: 10.1038/s41375-020-0765-5.

• BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.

  Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR.
  Science. 2020 Aug 21;369(6506):942-949. doi: 10.1126/science.aay2767.

• An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.

  Wei J, Wang Yung-Hua, Lee CY, Truillet C, Oh DY, Xu Yichen, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ.
  Mol Imaging Biol. 2020 Aug 19. doi: 10.1007/s11307-020-01527-3.

• Old dogs, new trick: classic cancer therapies activate cGAS.

  Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Yum Seoyun, Li M, Chen ZJ.
  Cell Res. 2020 Aug;30(8):639-648. doi: 10.1038/s41422-020-0346-1.

• 177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer.

  Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, Pinchuk AN, Bitton AN, Patel R, Zhang R, Rao AV, Iyer G, Engle JW, Weichert JP.
  J Nucl Med. 2020 Aug;61(8):1187-1194. doi: 10.2967/jnumed.119.236265.

• Tissue- and development-stage-specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples.

  Panda A, Yadav A, Yeerna H, Singh A, Biehl M, Lux M, Schulz A, Klecha T, Doniach S, Khiabanian H, Ganesan S, Tamayo P, Bhanot G.
  Nucleic Acids Res. 2020 Jul 27;48(13):7079-7098. doi: 10.1093/nar/gkaa485.

• Transcriptomic Profile of Lymphovascular Invasion, a Known Risk Factor of Pancreatic Ductal Adenocarcinoma Metastasis.

  Takahashi H, Katsuta E, Yan L, Tokumaru Y, Katz MHG, Takabe K.
  Cancers (Basel). 2020 Jul 24;12(8):2033. doi: 10.3390/cancers12082033.

• In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response.

  Baniel CC, Heinze CM, Hoefges A, Sumiec EG, Hank JA, Carlson PM, Jin WJ, Patel RB, Sriramaneni RN, Gillies SD, Erbe AK, Schwarz CN, Pieper AA, Rakhmilevich AL, Sondel PM, Morris ZS.
  Front Immunol. 2020 Jul 24;11:1610. doi: 10.3389/fimmu.2020.01610.

• The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis.

  Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gililland MG III, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, Hill BD, Rizvi SM, Wen F, Bishu S, Inohara N, Eaton KA, Nusrat A, Lei YL, Giannobile WV, Kamada N.
  Cell. 2020 Jul 23;182(2):447-462.e14. doi: 10.1016/j.cell.2020.05.048.

• A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

  Castellarin M, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH.
  JCI Insight. 2020 Jul 23;5(14):e136012. doi: 10.1172/jci.insight.136012.

• Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response.

  Dhanwani R, Takahashi M, Mathews IT, Lenzi C, Romanov A, Watrous JD, Pieters B, Hedrick CC, Benedict CA, Linden J, Nilsson R, Jain M, Sharma S.
  Sci Adv. 2020 Jul 22;6(30):eaba3688. doi: 10.1126/sciadv.aba3688.

• Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway.

  Zhang X, Bai X, Chen ZJ.
  Immunity. 2020 Jul 14;53(1):43-53. doi: 10.1016/j.immuni.2020.05.013.

• Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer.

  Tsuju T, Eng KH, Matsuzaki J, Battaglia S, Szender JB, Miliotto A, Gnjatic S, Bshara W, Morrison CD, Lele S, Emerson RO, Wang J, Liu S, Robins H, Lugade AA, Odunsi K.
  Oncotarget. 2020 Jul 7;11(27):2669-2683. doi: 10.18632/oncotarget.27666.

• Anti-MUC1-C Antibody-conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

  Detappe A, Mathieu C, Jin C, Agius M, Diringer MC, Tran VI, Pivot X, Lux F, Tillement O, Kufe D, Ghoroghchian PP.
  Int J Radiat Oncol Biol Phys. 2020 Jul 4;S0360-3016(20)31389-4.

• Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

  Frigault MJ, Nikiforow S, Mansour MK, Hu Z, Horowitz MM, Riches ML, Hematti P, Turtle CJ, Zhang M, Perales M, Pasquini MC.
  Blood. 2020 Jul 2; 136(1): 137–139.

• B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.

  Kim SS, Shen S, Miyauchi S, Sanders PD, Franiak-Pietryga I, Mell L, Gutkind JS, Cohen EEW, Califano JA, Sharabi DB.
  Clin Cancer Res. 2020 Jul 1;26(13):3345-3359. doi: 10.1158/1078-0432.CCR-19-3211.

• Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy.

  Chai J, Zhang H, Zhou J, Wu Z, Chen T, Papadopoulos E, Dowling CM, Pyon V, Pan Y, Liu JB, Bronson RT, Silver H, Lizotte PH, Deng J, Campbell JD, Sholl LM, Ng C, Tsao M, Thakurdin C, Bass AJ, Wong K.
  Clin Cancer Res. 2020 Jul 1;26(13):3431-3442. doi: 10.1158/1078-0432.CCR-19-1627.

• Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

  Eguchi A, Yan R, Pan SQ, Wu R, Kim J, Chen Y, Ansong C, Smith RD, Tempaku M, Ohno-Machado L, Takei Y, Feldstein AE, Tsukamoto H.
  J Mol Med (Berl). 2020 Jul;98(7):1021-1034. doi: 10.1007/s00109-020-01926-7.

• In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.

  Clark PA, Sriramaneni RN, Jin WJ, Jagodinsky JC, Bates AM, Jaquish AA, Anderson BR, Le T, Lubin JA, Chakravarty I, Arthur IS, Heinze CM, Guy EI, Kler J, Klar KA, Carlson PM, Kim KM, Kuo JS, Morris ZS.
  J Immunother Cancer. 2020 Jul;8(2):e000809. doi: 10.1136/jitc-2020-000809.

• BayesNetBP: An R Package for Probabilistic Reasoning in Bayesian Networks.

  Yu H, Janhavi M, Blair RH.
  Journal of Statistical Software. 2020 Jun 30;94(3):1213. doi: 1 10.18637/jss.v094.i03.

• Recapitulation of prostate tissue cell type-specific transcriptomes by an in vivo primary prostate tissue xenograft model.

  Gross NT, Wang J, Fiandalo, Gomez EC, Watts A, Godoy AS, Smith GJ, Wu Y.
  PLoS One. 2020 Jun 25;15(6):e0233899. doi: 10.1371/journal.pone.0233899.

• Intratumoral CD4⁺ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.

  Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friendlander TW, Ye CJ, Fong L.
  Cell. 2020 Jun 25; 181(7): 1612–1625.e13.

• IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.

  Zhou T, Damsky W, Weizman O, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, Sanmamed MF, Bosenburg MW, Ring AM.
  Nature. 2020 Jun 24. doi: 10.1038/s41586-020-2422-6.

• MUC1-C drives stemness in progression of colitis to colorectal cancer.

  Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D.
  JCI Insight. 2020 Jun 18;5(12):137112. doi: 10.1172/jci.insight.137112.

• Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

  Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, the IOTN Consortium, Odunsi A.
  J Immunother Cancer. Jun 17 2020; 8(1): e000796.

• CoMut: Visualizing integrated molecular information with comutation plots.

  Crowdis J, He MX, Reardon B, Van Allen EM.
  Bioinformatics. 2020 Jun 5;btaa554. doi: 10.1093/bioinformatics/btaa554.

• Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.

  Fuca G, Reppel L, Landoni E, Savoldo B, Dotti G.
  Clin Cancer Res. 2020 Jun 1;26(11):2444-2451.

• ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer

  Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW.
  Cancer Res. 2020 Jun 1;80(11):2094-2100. doi: 10.1158/0008-5472.CAN-19-3126.

• Cannabinoids promote progression of HPV positive head and neck squamous cell carcinoma via p38 MAPK activation.

  Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saito Y, Guo T, Tamayo P, Yeerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA.
  Clin Cancer Res. 2020 Jun 1;26(11):2693-2703. doi: 10.1158/1078-0432.CCR-18-3301.

• Adoptive T cell therapy: Boosting the immune system to fight cancer.

  Leon E, Ranganathan R, Savoldo B.
  Semin Immunol. 2020 Jun;49:101437. doi: 10.1016/j.smim.2020.101437.

• Humoral immune responses: Unsung heroes of the war on cancer.

  Conejo-Garcia JR, Biswas S, Chaurio R.
  Semin Immunol. 2020 Jun;49:101419. doi: 10.1016/j.smim.2020.101419.

• Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.

  Liu C, Sadat SH, Ebisumoto K, Sakai A, Panuganti BA, Ren S, Goto Y, Haft S, Fukusumi T, Ando M, Saita Y, Guo T, Tamayo P, Teerna H, Kim W, Hubbard J, Sharabi AB, Gutkind JS, Califano JA.
  Clin Cancer Res. 2020 Jun 1;26(11):2693-2703. doi: 10.1158/1078-0432.CCR-18-3301.

• Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.

  Lu T, Tang J, Shrestha B, Heath BR, Hong L, Lei YL, Ljungman M, Neamati N.
  Theranostics. 2020 May 25;10(15):6959-6976. doi: 10.7150/thno.41792.

• CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies.

  Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME.
  J Am Acad Dermatol. 2020 May 24;S0190-9622(20)30962-2. doi: 10.1016/j.jaad.2020.03.131.

• CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events.

  Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
  J Am Acad Dermatol. 2020 May 23;S0190-9622(20)30963-4. doi: 10.1016/j.jaad.2020.03.132.

• Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.

  Takahashi H, Oshi M, Asaoka M, Yan L, Endo I, Takabe K.
  Ann Surg Oncol. 2020 May 20. doi: 10.1245/s10434-020-08608-1.

• Tumor-Targeted Inhibition of Monocarboxylate Transporter 1 Improves T-Cell Immunotherapy of Solid Tumors.

  Huang T, Feng Q, Wang Z, Li W, Sun Z, Wilhelm J, Huang G, Vo T, Sumer BD, Gao J.
  Adv Healthc Mater. 2020 May 19;e2000549. doi: 10.1002/adhm.202000549.

• New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

  Williams KB, Largaespada DA.
  Genes (Basel). 2020 May; 11(5): 477.

• Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers.

  Shalapour S, Karin M.
  Annu Rev Immunol. 2020 Apr 26;38:649-671. doi: 10.1146/annurev-immunol-082019-081656.

• Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.

  Lundh S, Jung IY, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.
  Clin Exp Med. 2020 Apr 24. doi: 10.1007/s10238-020-00628-1.

• Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.

  Lundh S, Jung I, Dimitri A, Vora A, Melenhorst JJ, Jadlowsky JK, Fraietta JA.
  Clin Exp Med. 2020 Apr 24. doi: 10.1007/s10238-020-00628-1.

• Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.

  Zhang D, Hu Q, Liu X, Ji Y, Chao H, Liu Y, Tracz A, Kirk J, Buonamici S, Zhu P, Wang J, Liu S, Tang DG.
  Nat Commun. Apr 2020; 11: 2089.

• Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments.

  Jagodinsky JC, Morris ZS.
  Semin Radiat Oncol. 2020 Apr;30(2):181-186. doi: 10.1016/j.semradonc.2019.12.008.

• Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

  Brightman SE, Naradikian MS, Miller AM, Schoenberger SP.
  J Leukoc Biol. 2020 Apr;107(4):625-633. doi: 10.1002/JLB.5RI0220-603RR.

• Immunotherapy, Inflammation and Colorectal Cancer.

  Lichtenstern CR, Ngu RK, Shalapour S, Karin M.
  Cells. 2020 Mar 4;9(3):618. doi: 10.3390/cells9030618.

• Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.

  Yang Y, Jain RK, Glenn ST, Xu B, Singh PK, Wei L, Hu Q, Long M, Hutson N, Wang J, Battaglia S, George S.
  J Immunother Cancer. Mar 2020; 8(1): e000128.

• KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

  Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, McGuirk J, Oran B, Farag SS, Shore T, Van Besien K, Marsh SGE, Guethlein LA, Parham P, Miller JS.
  Blood Adv. 2020 Feb 25; 4(4): 740–754.

• HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING.

  Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL.
  J Clin Invest. 2020 Feb 24. pii: 129497. doi: 10.1172/JCI129497.

• Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers.

  Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, Hu Q, Liu S, Black DL, Witte ON, Xing Y.
  Proc Natl Acad Sci U S A. 2020 Feb 21. pii: 201915975. doi: 10.1073/pnas.1915975117.

• HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

  Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB.
  Cancer Res. 2020 Feb 15;80(4):732-746. doi: 10.1158/0008-5472.CAN-19-1771.

• CRISPR-engineered T cells in patients with refractory cancer.

  Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Piesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.
  Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365.

• CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

  Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter Dl, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD.
  J Clin Invest. 2020 Feb 3;130(2):673-685. doi: 10.1172/JCI130144.

• Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.

  Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L.
  Cancer Immunol Res. 2020 Feb;8(2):246-254. doi: 10.1158/2326-6066.CIR-19-0359.

• In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.

  Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatliogu E, Almonte C, Labbe K, Silver H, Rabin AR, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman PS, Velcheti V, Freeman GJ, Qi J, Miller G, Wong KK.
  Cancer Discov. 2020 Feb;10(2):270-287. doi: 10.1158/2159-8290.CD-19-0780.

• Orchestrating single-cell analysis with Bioconductor.

  Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Soneson C, Waldron L, Pagès H, Smith ML, Huber W, Morgan M, Gottardo R, Hicks SC.
  Nat Methods. 2020 Feb;17(2):137-145. doi: 10.1038/s41592-019-0654-x.

• Filmed over with CAR-T cells.

  Adu-Berchie K, Mooney DJ.
  Nat Biomed Eng. 2020 Feb;4(2):142-143. doi: 10.1038/s41551-020-0517-x.

• Stearoyl-CoA desaturase and tumorigenesis.

  Kikuchi K, Tsukamoto H.
  Chem Biol Interact. 2020 Jan 25;316:108917. doi: 10.1016/j.cbi.2019.108917.

• MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

  Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
  Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6.

• CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer.

  Kemnade JO, Elhalawani H, Castro P, Yu J, Lai S, Ittmann M, Mohamed ASR, Lai SY, Fuller CD, Sikora AG, Sandulache VC.
  Sci Rep. 2020 Jan 14;10(1):243. doi: 10.1038/s41598-019-57111-5.

• CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer.

  Kemnade JO, Elhalawani H, Castro P, Yu J, Lai S, Ittmann M, Mohamed ASR, Lai SY, Fuller CD, Sikora AG, Sandulache VC.
  Sci Rep. 2020 Jan 14;10(1):243. doi: 10.1038/s41598-019-57111-5.

• STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cell.

  Kim JW, Berrios C, Kim M, Schade AE, Adelmant G, Yeerna H, Damato E, Iniguez AB, Florens L, Washburn MP, Stegmaier K, Gray NS, Tamayo P, Gjoerup O, Marto JA, DeCaprio J, Hahn WC.
  Elife. 2020 Jan 8;9:e53003. doi: 10.7554/eLife.53003.

• The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.

  Hou J, Zhang H, Sun B, Karin M.
  J Hepatol. 2020 Jan;72(1):167-182. doi: 10.1016/j.jhep.2019.08.014.

• Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

  Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.
  Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980.

• Log-epsilon-skew normal: A generalization of the log-normal distribution.

  Hutson AD, Mashtare Jr TL, Mudholkar GS.
  Commun Stat Theory Methods. 2020;49(17):4197-4215. doi: 10.1080/03610926.2019.1595655.

• Exploiting nanoscale cooperativity for precision medicine.

  Wilhelm J, Wang Z, Sumer BD, Gao J.
  Adv Drug Deliv Rev. 2020;158:63-72. doi: 10.1016/j.addr.2020.08.012.

• Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.

  Lu T, Tang J, Shrestha B, Heath BR, Hong L, Lei YL, Ljungman M, Neamati N.
  Theranostics. 2020; 10(15): 6959–6976.